Seongwoo Yang1,*, Ji Won Park2,*, Hyuk Hur3,5, Min Jung Kim2 , Seung-Yong Jeong2 , Kyounghoon Park1 , Ik Yong Kim4,5

1 HERINGS, The Institute of Advanced Clinical & Biomedical Research, Seoul; 2 Department of Surgery, Seoul National University College of Medicine, Seoul; 3 Department of Surgery, Yonsei University College of Medicine, Seoul; 4 Division of Colorectal Surgery, Department of Surgery, Yonsei University Wonju College of Medicine, Wonju; 5 Korean Wound and Ostomy Study Group of The Korean Society of Coloproctology, Seoul, Korea

Purpose: The use of an ostomy for urination and defecation leads to reduced quality of life. Although many ostomy management strategies are needed, such strategies are often implemented by patients. Thus, there is a need for a home health

care service platform that can be used in ostomy patient management.

Methods: We developed an ostomy patient management platform by identifying the needs of patients and medical staff through the Chronic Care Ostomy Self-Management Training Program in the United States and from studies conducted in Korea.

Results: The platform encompassed physical management, psychological management, maintenance of social function, spiritual stability, and home medical care. These components were implemented through monitoring, self-care guidance, and a community platform. For the monitoring function, a patient entered their health status in a mobile application (app); the medical staff at the affiliated hospital then monitored the stoma status through a web interface.

Conclusion: Our platform allows medical staff to monitor ostomy patients through a web interface and help such patients to fully manage their ostomy at home using an app. We expect that the continued development of patient-oriented functions in our app will allow ostomy patients to experience quality of life improvements.

Keywords: Ostomy; Home care services; Telehealth; Digital health platform; Telemedicine

Received: May 23, 2022 • Revised: Jul 12, 2022 • Accepted: Jul 18, 2022 Correspondence to: Kyounghoon Park, M.D., Ph.D. HERINGS, The Institute of Advanced Clinical & Biomedical Research, 560 Eonju-ro, Gangnam-gu, Seoul 06144, Korea

Tel: +82-2-6949-3516, Fax: +82-2-6949-3517

E-mail: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

ORCID: https://orcid.org/0000-0001-5800-917X Co-Correspondence to: Ik Yong Kim, M.D., Ph.D. Department of Surgery, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju 26426, Korea

Tel: +82-33-741-0573, Fax: +82-33-741-0574

E-mail: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

ORCID: https://orcid.org/0000-0001-6375-2216

* Seongwoo Yang and Ji Won Park contributed equally to this work as co-first authors.

This study was presented at The Korean Society of Coloproctology the 55th Annual Meeting, held in Busan, Korea from April 8 to 10, 2022.

© 2022 The Korean Society of Coloproctology

This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Declan Doherty, Andy Bridgen, Aaron Barber and Frank Webb

The total contact cast (TCC) is considered the gold-standard treatment for plantar neuropathic ulceration and acute Charcot neuroarthropathy. There is little evidence on the risk of venous thromboembolism (VTE) associated with TCC treatment. It is widely accepted that routine VTE chemoprophylaxis is not required for neuropathic patients treated with a TCC. Aims: This study aimed to investigate the rate of symptomatic VTE in neuropathic patients with a TCC and to provide up-to-date information to guide future practice. Methods: A retrospective service evaluation was undertaken. The PASCOM-10 online database was utilised for data collection within a communitybased podiatric surgery unit. Patients treated with a TCC or TCC with Bohler walker for plantar ulceration or Charcot neuroarthropathy between 2019 and 2021 were identified. Data were reviewed to ascertain if any evidence of symptomatic VTE had been recorded during casting. Results: A total of 53 casting episodes in 40 patients were included. All patients had a diagnosis of peripheral neuropathy. The mean length of time in a cast was 51 days (range 14–161 days). No episodes of total contact casting resulted in a symptomatic VTE. Conclusion: The use of TCC did not increase the prevalence of VTE in this patient cohort. Larger, prospective studies are warranted to further investigate VTE risk in neuropathic patients treated with a TCC and the theorised VTE protective mechanisms in this patient population.

Citation: Doherty D, Bridgen A, Barber A, Webb F (2022) The prevalence of symptomatic venous thromboembolism in patients requiring total contact casting for neuropathic foot complications. The Diabetic Foot Journal 25(4): 50–6

Key words

- Bohler walker - Charcot neuroarthropathy - Total contact cast - Ulceration - Venous thromboembolism

Article points

1. There is little evidence on the risk of venous thromboembolism (VTE) associated with a total contact cast (TCC).

2. This study aimed to investigate the rate of symptomatic VTE in neuropathic patients with a TCC.

3. The use of TCC did not increase the prevalence of VTE in this patient cohort.

Authors

Declan Doherty is Trainee in Podiatric Surgery, Buxton Hospital, Buxton, Derbyshire, UK; Andy Bridgen is Senior Lecture in Podiatry and Postgraduate Course Leader, University of Huddersfield, Huddersfield, UK; Aaron Barber is Lead Podiatrist in Diabetes, Diabetes Centre, Barnsley Hospital, Barnsley, UK; Frank Webb is Consultant Podiatric Surgeon, Buxton Hospital, Buxton , UK.

Matthew J Young, Lesley ML Hall and Joshua D Jones

      The treatment of diabetic foot infections (DFIs) represents a costly and growing challenge to the NHS. DFIs can be difficult to treat for a variety of reasons, including late presentation of advanced infection, and antibiotic tolerance or resistance. Bacteriophage (phage) are ubiquitous viruses that infect and kill bacteria in a species-, sometimes even strain-, specific manner. Phages have been used to treat bacterial infection since 1919, but their use in the geopolitical West ceased in the 1930s due to a variety of factors, including the mass production of antibiotics. The modern antibiotic resistance crisis has driven renewed interest in phage therapy and 2,241 patients with mostly with antibiotic refractory infections have been treated since 2000, 79% of whom improved. This includes at least 310 patients with chronic wound infections, among whom 86.1% achieved clinical resolution or improvement of infection. Reassuringly, the available evidence suggests that phage therapy is safe and without notable side effects. Some phages also possess enzymes capable of degrading the biofilms that afford antibiotic tolerance to bacteria and underpin many chronic infections. Phages also act independent of antibiotic resistance, allowing the treatment of even pan-resistant bacteria, and topical or local application to DFIs means antimicrobial activity is independent of a patient’s peripheral perfusion. Presently only an option when antibiotics are not meeting a patient’s clinical needs, future integration of phage therapy at all levels of DFI care will radically transform the outlook for DFIs in the UK. Reducing the number of serious infections and amputations will not only benefit patients but will deliver vast savings to the NHS and reduce the amount of antibiotics used, making phage therapy a tangible response to the antibiotic resistance crisis.

Citation: Young MJ, Hall LML, Jones JD (2022) Phage therapy for diabetic foot infection. The Diabetic Foot Journal 25(4): 30–7

Key words - Bacteriophage  - Diabetic foot infection  - Phage therapy

Article points

1. Bacteriophages (phages) are viruses that infect and kill bacteria that can be used to treat infections, known as phage therapy.

2. The available evidence suggests that phage therapy is safe and effective for the treatment of wound infections.

3. Phage therapy has the potential to transform the care of diabetic foot infections.

Authors

      Matthew J. Young is Consultant Physician, Royal Infirmary of Edinburgh, Edinburgh, UK; Lesley ML Hall is Consultant Physician, Diabetes and Endocrinology, Queen Elizabeth University Hospital, Glasgow, UK; Joshua D Jones is Consultant Physician, Infection Medicine, Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, UK; Clinical Microbiology, Ninewells Hospital, NHS Tayside, Dundee, UK

David Morris

There is strong evidence that early-onset type 2 diabetes (commonly defined as that occurring in people under the age of 40 years) is a more aggressive condition than late-onset type 2 diabetes. The longer period of exposure to the risk factors of hyperglycaemia, hypertension and hyperlipidaemia and the more rapid progression of disease itself renders the individual more vulnerable to developing both microvascular and macrovascular complications at an earlier age. Early recognition and management of type 2 diabetes in younger people and public health messaging aimed at prevention of type 2 diabetes will be crucial to dealing with the problem. This article outlines the diagnosis, clinical implications and management of early-onset type 2 diabetes, with a particular focus on younger adults (rather than children and adolescents), in whom the condition is more common, and who are likely to be managed in primary care.

Citation: Morris D (2022) Early-onset type 2 diabetes: Clinical implications, diagnosis and management. Journal of Diabetes Nursing 26: [Early view publication]

Article points

Article points

1. The incidence of early-onset type 2 diabetes is increasing, with important individual health and socioeconomic consequences.

2. Individuals with early-onset type 2 diabetes experience more rapid progression of microvascular and cardiovascular complications than those with type 1 diabetes and those who develop type 2 diabetes in later years.

3. The presence of islet cell autoantibodies is predictive of future insulin requirement and the development of other autoimmune diseases.

4. If there is uncertainty about the type of diabetes in a child or young adult, it is safer to manage as type 1 diabetes and treat with insulin.

5. A holistic approach to earlyonset type 2 diabetes is essential. Socioeconomic status and psychological issues need to be taken into account.

Key words

- Children and young people - Early-onset type 2 diabetes

Author

David Morris, Specialist Doctor in Diabetes, Royal Shrewsbury Hospital; Clinical Undergraduate Tutor, Keele University; and retired GP